Wood Mark Form 4 January 23, 2009

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

if no longer subject to

Section 16. Form 4 or Form 5 obligations may continue. See Instruction STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

(Print or Type	Responses)									
Name and Address of Reporting Person * Wood Mark			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [BMRN]				6	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)		
(Last) (First) (Middle)  C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 01/22/2009					Director 10% Owner X_ Officer (give title Other (specify below) below)  VP, Human Resources		
NOVATO,		4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tabl	le I - Non-	Derivative	Secui	rities Acqu	ired, Disposed of	f, or Beneficiall	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	Code (Instr. 8)	4. Securior(A) or D (Instr. 3,	ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/21/2009(1)	01/21/20	009	M	177	A	\$ 6.13	827	D	
Common Stock	01/21/2009(1)	01/21/20	009	S	177	D	\$ 19.296 (2)	650	D	
Common Stock	01/22/2009(1)	01/22/20	)09	M	1	A	\$ 6.13	651	D	
Common Stock	01/22/2009(1)	01/22/20	009	S	1	D	\$ 19.05	650	D	

**OMB APPROVAL** 

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

#### Edgar Filing: Wood Mark - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 6.13	01/21/2009	01/21/2009	M	177	07/07/2005(3)	01/06/2015	Common Stock	177
Stock Option (right to buy)	\$ 6.13	01/22/2009	01/22/2009	M	1	07/07/2005(3)	01/06/2015	Common Stock	1

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Oxyman	Officer	Other		

Director 10% Owner Officer Other

Wood Mark

C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE

VP, Human Resources

NOVATO, CA 94949

## **Signatures**

G. Eric Davis, Attorney-In-Fact

\*\*Signature of Reporting Person Date

Reporting Owners 2

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 Trading Plan executed August 23, 2007, as amended on May 21, 2008.
  - The price in Column 4 is a weighted average price. The prices actually received ranged from \$19.11 to \$19.53. The reporting person will
- (2) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) Original option grant vested 6/48ths on July 7, 2005 and 1/48th on the 7th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.